On 1st December 2023, the pharmaceutical company Seelos Therapeutics announced they had stopped their phase 2/3 programme known as STRIDES, which had been investigating a new drug for Spinocerebellar Ataxia Type-3 (SCA3)/ Machado-Joseph Disease, known as Trehalose. Seelos had planned to recruit 245 people with SCA3 to their phase 2/3 randomised study looking at the safety and efficacy of Trehalose compared to placebo.
You can read about the research, and how Trehalose has been tested for the treatment of SCA3, here.
Seelos said that the decision to terminate recruitment and stop the trial was based on financial considerations, and not due to data on safety concerns or the therapeutic effects of the drug in SCA3.
To read more, click here.
